国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
International Journal of Urology and Nephrology
2015年
5期
716-718
,共3页
腺癌,透明细胞%肾肿瘤
腺癌,透明細胞%腎腫瘤
선암,투명세포%신종류
Adenocarcinoma,Clear Cell%Kidney Neoplasms
目的 探讨舒尼替尼治疗转移性肾癌的疗效及不良反应.方法 舒尼替尼治疗转移性肾透明细胞癌35例,其中肺部转移27例,骨转移8例.观察治疗后肿瘤病灶的变化及患者服用药物后的不良反应及处理.结果 35例患者均能坚持完成治疗方案,平均随访18.7个月,有效率82.8％.其中有12例因不良反应给予暂时停药或减少剂量.结论 舒尼替尼治疗转移性肾癌有效率高,不良反应发生率也较高,通过加强随访并及时处理可以减轻患者不良反应,有利于药物治疗的继续进行.
目的 探討舒尼替尼治療轉移性腎癌的療效及不良反應.方法 舒尼替尼治療轉移性腎透明細胞癌35例,其中肺部轉移27例,骨轉移8例.觀察治療後腫瘤病竈的變化及患者服用藥物後的不良反應及處理.結果 35例患者均能堅持完成治療方案,平均隨訪18.7箇月,有效率82.8％.其中有12例因不良反應給予暫時停藥或減少劑量.結論 舒尼替尼治療轉移性腎癌有效率高,不良反應髮生率也較高,通過加彊隨訪併及時處理可以減輕患者不良反應,有利于藥物治療的繼續進行.
목적 탐토서니체니치료전이성신암적료효급불량반응.방법 서니체니치료전이성신투명세포암35례,기중폐부전이27례,골전이8례.관찰치료후종류병조적변화급환자복용약물후적불량반응급처리.결과 35례환자균능견지완성치료방안,평균수방18.7개월,유효솔82.8％.기중유12례인불량반응급여잠시정약혹감소제량.결론 서니체니치료전이성신암유효솔고,불량반응발생솔야교고,통과가강수방병급시처리가이감경환자불량반응,유리우약물치료적계속진행.
Objectives To investigate efficacy and adverse events of Sunitinib in treating advanced renal clear cell carcinoma.Methods A total of 35 renal clear cell carcinoma patients were treated with Sunitinib.Among them,27 patients had lung metastasis and 8 patients had bone metastasis.All patients received Sunitinib 50mg qd,4 weeks on and 2 weeks off.The alteration of the tumor site were recorded,and adverse events were recorded and treated.Results All 35 patients finished the treatment schedule.Average follow up 18.7 months.Sunitinib was effective for 86.4％ patients.In all patients,16 cases had dose reduced or temporary suspending.Conclusions Sunitinib was an efficient drug in treating advanced renal clear cell carcinoma.Although it has a high ratio of adverse events.Most of the patients can finish the treatment schedule.
